MIDAS Database for International Price Comparison

1. The purpose and explanation of an ACAN

An Advance Contract Award Notice (ACAN) allows the Patented Medicine Prices Review Board (PMPRB) to post a notice, for no less than fifteen (15) calendar days, indicating to the supplier community that a goods, services or construction contract will be awarded to a pre-identified contractor. If no other supplier submits, on or before the closing date, a Statement of Capabilities that meets the minimum requirements identified in the ACAN, the Contracting Authority may then proceed to award a contract to the pre-identified contractor.

2. Rights of suppliers

Suppliers who consider themselves fully qualified and available to provide the services or goods described in this ACAN may submit a Statement of Capabilities demonstrating how they meet the advertised requirement. This Statement of Capabilities must be provided via e-mail only to the contact person identified in Section 12 of the Notice, on or before the closing date and time of the Notice. If the Bidder can clearly demonstrate they possess the required capabilities, the requirements will be opened to electronic or traditional bidding processes.

3. Proposed Contractor

IMS AG

Doftplatz4,

6330 Cham

Switzerland

4. Definition of Requirements or Expected Results

The PMPRB has both a regulatory and reporting mandate. Comprehensive and accurate data on price and utilization domestically and internationally for all drugs is required to effectively fulfil both mandates.

With respect to the reporting mandate, the PMPRB is responsible for reporting on trends in pharmaceutical sales and pricing for all medicines and for reporting research and development spending by patentees.

The PMPRB requires drug utilization information for the retail and hospital sector respecting relevant market variables such as price (at ex-factory, wholesale and retail level in local and US currency), quantities and revenue of medicines sold in Canada and all OECD countries. The information must be collected in a complete, objective and non-biased fashion by surveying hospitals, pharmacies and wholesalers across Canada and all OECD countries. IMS AG has two products (IMS Midas Quantum Data Elements, Measure and Statistics, and IMS Midas Market Segmentation) which contain comprehensive detail level data not available from any other source.

The PMPRB, on an annual basis, develops a research agenda based on input from a National Prescription Drug Utilization Information System (NPDUIS) Advisory Committee (AC). The NPDUIS is a federal/provincial/territorial initiative that provides critical analysis of price, utilization, and cost trends to support policy-making by federal government and provincial public drug plans. The results of NPDUIS studies, which are generally conducted at the request of provincial or territorial partners, are often published in the form of research reports, analysis briefs, or presentations and made available to stakeholders and the general public.

International price and market trends continue to be areas of research for both PMPRB policy work and as part of research priorities identified by the NPDUIS AC.

5. Minimum requirements

Any interested supplier must demonstrate by way of a Statement of Capabilities that it meets the following minimum requirements:

A) Deliverables

Price, utilization and market and product information for all OECD countries for top selling 100 off-patent multiple source molecules; top selling 25 off-patent single source molecules; top selling 50 patented molecules for a minimum of ten years of historical data (manufacturer, wholesale and retail level data for in and out of patient sectors).

This database contains the following information:

• For 34 OECD countries, respective product price and sales comparison data where available, including 16 PMPRB specificd variables.
• OECD price and utilization information (by market segmentation: off-patent, patent, multiple source, single source, generics or unbranded, branded, company branded generics and original off-patent brand).
• Data should be grouped by three categories: top selling 100 off-patent multiple source molecules with generic copies in Canada and with generic sales in at least three other countries (listed below) for the same period; top selling 25 off-patent single source molecules in Canada; and 50 top selling patented drug products.
• Top selling is defined in Canada for latest 12 month of available sales data
• Prices, market segment and number of manufacturers information for all OECD countries for each group of drugs separated by market segment and time period
• For all OECD countries, include micro and macro data for all drug groupings, ie. off-patent multiple source, off patent single source and patented and include total quantity, number of prescriptions and cost (in local and US currency).
• All data (international data and Canadian data) to be separated by the hospital and retail sector and wholesale, retail and ex-factory gate level separated by market segment (as defined above).
• Number of unique manufacturers and corporations for each molecule and by market segment
• Product market protection information must be included.
• All data to include name and price at manufacturer level with a brand/generic identifier and multiple/single source identifier. Median, minimum and maximum price to be reported at hospital and retail level separately. Separated to the wholesale, retail and ex-factory gate level.
• Time period: most current 10 years
• Price information to be provided in local and US currency, by geographical area and years and quarter.
• Price for each category of drugs and market segment will be defined as a straight average of $/units.
• Information being reported at the following levels: time period (quarter), country, market segment, manufacturer, ingredient, strength, form, packsize.

Selected Data Elements (16)

1. Country
2. Sector
3. Corporation
4. Manufacturer
5. ATC4
6. International product name
7. Domestic Product name
8. Molecule
9. INTRX (prescription status)
10. GEN PRD (generic status)
11. E-DT PRTEXP (protection expiry date)
12. New Form Code 3
13. INTSTR (International Strength)
14. International Size (INTSIZE)
15. International Volume (INTVOL)
16. Chemical Salt

Specifications and Standards

• Top selling is defined by Canadian market
• Price is defined as average price per counting units
• The results shall be provided in Microsoft Excel, flat comma delimited files and/or other compatible software

6. Reason for non-competitive award

In accordance with the Government Contracts Regulations (GCR) of the Financial Administration Act, the following request falls under exception 6(d) of the GCR, which stipulates that only one person or contractor is capable of performing the contract.

IMS AG is the only company to collect the required information in the required complete, objective and non-biased fashion, by surveying hospitals, pharmacies as well as wholesalers across Canada and all other OECD countries. No other data supplier is known to provide the type of information that would be sufficient to meet the requirements. The data supplied will add to an already existing database with the same specifications and would allow for consistent time horizon analysis. IMS Health has exclusive ownership of the MIDAS database.

7. Applicable trade agreements and justification for limited tendering

This procurement is subject to the following:

AIT- Limited tendering reason; where there is an absence of competition for technical reasons and the goods or services can be supplied only by a particular supplier and no alternative or substitute exists, As per Article 506 Paragraph12 (b)

NAFTA- Limited tendering reason; the goods or services can be supplied only by a particular supplier and no reasonable alternative or substitute exists, As per Article 1016.2(B)

WTO- Limited tendering reason; the products or services can be supplied only by a particular supplier and no reasonable alternative or substitute exists, As per Article XV (15), Paragraph 1 (b)

8. Ownership of Intellectual Property

Ownership of any Foreground Intellectual Property arising out of the proposed contract will vest with the Contractor.

9. Period of the proposed contract

The services of the contractor will be required for five years after the award of the contract.

10. Estimated value of the proposed contract

The total estimated value of the proposed contract should not exceed $1,198,378.00 US including all 5 year option periods.

11. Closing date and time

The closing date and time for accepting Statements of Capabilities is January 25, 2016 at 14:00h EST.

12. Contact Person

All inquiries with regard to this Notice must be addressed by e-mail to:

Name: Nadia Laneve

E-Mail: nadia.laneve@pmprb-cepmb.gc.ca